Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will be participating in the following investor conferences: Jefferies Healthcare Conference Date:
Isaralgagene civaparvovec, or ST-920, continued to be generally well tolerated across three dose cohorts in the five treated patients - In the first two dose cohorts, all four patients exhibited above
PARIS (dpa-AFX) - Genomic medicines company Sangamo Therapeutics, Inc. (SGMO) announced Thursday that French drug major Sanofi (SNYNF, SNY) will be transitioning its rights and obligations related
No adverse events related to investigational SAR445136 were reported - All four treated patients experienced increases in total hemoglobin, fetal hemoglobin and percent F cells; none required blood
Pfizer Inc. (NYSE: PFE) andSangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today announced updated follow-up data from the Phase 1/2 Alta study of giroctocogene fitelparvovec